The myocardial area at risk
暂无分享,去创建一个
[1] N. Keating,et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. , 2012, Journal of the National Cancer Institute.
[2] R. Kim,et al. Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction , 2011, Heart.
[3] R. Kim,et al. T2-weighted imaging to assess post-infarct myocardium at risk. , 2011, JACC. Cardiovascular imaging.
[4] G. Schuler,et al. Myocardium at risk in ST-segment elevation myocardial infarction comparison of T2-weighted edema imaging with the MR-assessed endocardial surface area and validation against angiographic scoring. , 2011, JACC. Cardiovascular imaging.
[5] N. Tanaka,et al. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. , 2011, Japanese journal of clinical oncology.
[6] P. Walsh. Re: Statin Medication Use and the Risk of Biochemical Recurrence After Radical Prostatectomy: Results From the Shared Equal Access Regional Cancer Hospital (SEARCH) Database , 2011 .
[7] Stacey A. Kenfield,et al. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Doll,et al. Lifestyle Intervention in Men with Advanced Prostate Cancer Receiving Androgen Suppression Therapy: A Feasibility Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[9] A. Kibel. Combined Resistance and Aerobic Exercise Program Reverses Muscle Loss in Men Undergoing Androgen Suppression Therapy for Prostate Cancer Without Bone Metastases: A Randomized Controlled Trial , 2010 .
[10] J. Kaufman,et al. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis , 2010, Heart.
[11] A. D'Amico. Is long-term androgen suppression right for everyone with locally advanced prostate cancer? , 2010, The Lancet. Oncology.
[12] C. L. Cutajar,et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.
[13] P. Morris,et al. Low serum testosterone and increased mortality in men with coronary heart disease , 2010, Heart.
[14] P. Kellman,et al. Magnetic Resonance Imaging Delineates the Ischemic Area at Risk and Myocardial Salvage in Patients With Acute Myocardial Infarction , 2010, Circulation. Cardiovascular imaging.
[15] Mats Lambe,et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. D'Amico,et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. , 2010, Circulation.
[17] C. Lawton. Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31 , 2010 .
[18] A. Meikle. Low circulating androgens and mortality risk in heart failure , 2010 .
[19] C. Lawton. Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31 , 2010 .
[20] A. D'Amico,et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. , 2009, JAMA.
[21] S. Dymarkowski,et al. Quantification of myocardial area at risk with T2-weighted CMR: comparison with contrast-enhanced CMR and coronary angiography. , 2009, JACC. Cardiovascular imaging.
[22] J. Schulz-Menger,et al. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.
[23] D. Nathan,et al. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. , 2008, Urology.
[24] Andrew E Arai,et al. In Vivo T2-Weighted Magnetic Resonance Imaging Can Accurately Determine the Ischemic Area at Risk for 2-Day-Old Nonreperfused Myocardial Infarction , 2008, Investigative radiology.
[25] I. Derweesh,et al. Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer , 2007, BJU international.
[26] Daniel C. Lee,et al. Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. , 2007, European heart journal.
[27] A. D'Amico,et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Dobs,et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. F. Hoyt,et al. Cardiac magnetic resonance imaging , 2004, Postgraduate Medical Journal.
[30] D. Nathan,et al. Insulin sensitivity during combined androgen blockade for prostate cancer. , 2006, The Journal of clinical endocrinology and metabolism.
[31] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[32] A. Lenzi,et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle‐aged men: a meta‐analysis , 2005, Clinical endocrinology.
[33] Fernando Costa,et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.
[34] C. Bulpitt,et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. , 2003, Clinical science.
[35] P. Nguyen,et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma , 2002, Cancer.
[36] O. Simonetti,et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. , 1999, Circulation.
[37] J. Gili,et al. Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. , 1993, Cardiovascular research.
[38] J L Duerk,et al. Distinguishing viable from infarcted myocardium after experimental ischemia and reperfusion by using nuclear magnetic resonance imaging. , 1990, Journal of the American College of Cardiology.
[39] T J Brady,et al. Effect of hyperosmotic mannitol on magnetic resonance relaxation parameters in reperfused canine myocardial infarction. , 1989, Magnetic resonance imaging.
[40] B R Rosen,et al. Assessment of myocardial ischemia with proton magnetic resonance: effects of a three hour coronary occlusion with and without reperfusion. , 1985, Circulation.
[41] E S Kirk,et al. The Microcirculation of the Human Heart: End‐capillary Loops with Discrete Perfusion Fields , 1982, Circulation.
[42] R E Ideker,et al. Myocardial Infarct Size and Location in Relation to the Coronary Vascular Bed at Risk in Man , 1981, Circulation.
[43] Reimer Ka,et al. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979 .
[44] R. Jennings,et al. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. , 1979, Laboratory investigation; a journal of technical methods and pathology.